All News
The Inflammation Reflex (5.20.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.
Read Article
#LB0002 #EULAR2022 An interesting study design looking at flare rate following withdrawal of drug after WK12. Phase 3 RCT of Baricitinib in paediatric JIA showed 76% met ACR30 at WK12. The Double-blind withdrawal showed less patients on Bari flared vs PBO (17% vs 51%) @RheumNow https://t.co/T0mSDkoHJo
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2022 LB002
P3 Double-Blind W/d study: Baricitinib for JIA
⭐️All pts start in open label w good benefit (1/2 with ACR70)
⭐️PBO W/d led to 50% flare vs 17% in BARI group, flares earlier
@RheumNow https://t.co/apSSLqu1mp
Eric Dein ericdeinmd ( View Tweet)
JUVE-BASIS Baricitinib in JIA
Phase 3 RCT wk12
Cs or BioDMARDs IR
⚡️Time to disease flare HR 0.24
⚡️JIA-ACR50% 63%
⚡️% flares 17% vs. 50% in PBO
Safety profile similar than adults
@RheumNow
#EULAR2022 LB0002 https://t.co/dX3DpB4QHT
Aurelie Najm AurelieRheumo ( View Tweet)
Quote of the day “Don’t be too quick to call it negative” by Marco Gattorno on looking for systemic Autoinflammatory disease (SAID) when there is the clinical suspicion #EULAR2022 @RheumNow https://t.co/SjARIlDjtR
Dr. Antoni Chan synovialjoints ( View Tweet)
So what diet to follow with autoimmunity in mind?
So many, all with different instructions.
Let’s concentrate on where they agree:
yes to fruits & vegetables
no to emulsifiers & processed foods
#EULAR2022 @RheumNow https://t.co/I9abweQOyZ
David Liew drdavidliew ( View Tweet)
JAK will quiet Still’s disease? 7 w Still’s 4 refractory disease had benefit w #JAKi POS0014. Needs more data but looks promising most w partial response . 5 on #Tofacitinib and 2 w #Baricitinib. @eular_org #EULAR2022 POS0014 @RheumNow https://t.co/j9IRgT9XJf
Janet Pope Janetbirdope ( View Tweet)
Brevet et al. SAPHO syndrome. Divided into bone group and joint/mixed group. Better response to bisphosphonate in bone group 60% vs 6%. Better response to DMARD in joint/mixed group 94% vs 40% @RheumNow #EULAR2022 POS1333 https://t.co/FfYBIEGGgJ
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 – Day 2 Report
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, and fibromyalgia.
https://t.co/dpq5Het2rN https://t.co/NIfkjhHw86
Links:
Dr. John Cush RheumNow ( View Tweet)
The expanding spectrum of Systemic Autoinflammatory Disease (SAID) by Marco Gattorno using a combination of clinical assessment, genetic testing and imaging to define the phenotype of SAID #EULAR2022 @RheumNow https://t.co/TGYmfExHxD
Dr. Antoni Chan synovialjoints ( View Tweet)
#Behcets. If topical oracort / steroids don’t work for Mucosal ulcers consider topical #tacrolimus https://t.co/7ZiLfdwZoP
Janet Pope Janetbirdope ( View Tweet)
Behcet disease:
RCT Topical Tacrolimus for mouth ulcers in 40+pts
↘️VAS 2 wks & 3mo
↘️ Number of ulcers
↘️ Ulcer size and duration
↘️ Ulcer severity score
#OP0046 #EULAR2022 @RheumNow
Aurelie Najm AurelieRheumo ( View Tweet)
Long-term canakinumab data in FMF from RELIANCE registry. 63% in remission at month 24. @RheumNow #EULAR2022 OP0042 https://t.co/mEIoAszmZq https://t.co/IvR1cSG4Aq
Links:
Richard Conway RichardPAConway ( View Tweet)
Can be challenging to identify early/impending MAS in AoSD. Ruscitti et al propose a model based on systemic score, ferritin, IFN-γ, and IL-10 with AUC 0.99, sensitivity 100% specificity 95% @RheumNow #EULAR2022 OP0044 https://t.co/bbWkdGCnHP
Links:
Richard Conway RichardPAConway ( View Tweet)
TOFFIFE RCT in colchicine-resistant FMF. Tocilizumab normalises SAA and CRP/ESR with PGA response in 20-25%. Maybe response criteria too strict, or maybe TCZ only effective for subgroup of patients @RheumNow #EULAR2022 OP0043 https://t.co/kNs8DMzXFB https://t.co/QMDk1IUkjx
Links:
Richard Conway RichardPAConway ( View Tweet)
Looking forward to reading/watching the coverage of #EULAR2022 by our outstanding faculty, including Drs., Rachel Tate @uptoTate, Kathryn Dao @KDAO2011,
Robert Chao @doctorRBC , Janet Pope @Janetbirdope and Antoni Chan @synovialjoints . https://t.co/oBQCxzdzfF
Dr. John Cush RheumNow ( View Tweet)
To TDM or Not in Rheumatology?
Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. But now, EULAR has a recommendation...
https://t.co/u86Vd8bFGr
#MedEdTwitter https://t.co/IpKqPoWM9R
Links:
Dr. John Cush RheumNow ( View Tweet)
It's our 8th year covering this important meeting! Join us June 1 - 4 for key opinion leader perspectives, clinical trial highlights and more, as we cover #EULAR2022. https://t.co/eHziBN3TWk
Dr. John Cush RheumNow ( View Tweet)
Ontario population study shows that musculoskeletal disorders account for 12.3% of all adult emergency dept. visits and 28.5% outpatient physician visits https://t.co/Sq9n7RkIYK https://t.co/lKtQqR5Ja3
Links:
Dr. John Cush RheumNow ( View Tweet)
Differential diagnosis of dysphagia - when due to autoimmune dz is called Autoimmune neurogenic dysphagia - causes include inflammatory myopathies,inclusion body myositis, myasthenia gravis, Guillain–Barre, MS, NMO, paraneoplastic neuropathies https://t.co/oA0cPVJ5pJ https://t.co/58MyQwmxhL
Links:
Dr. John Cush RheumNow ( View Tweet)
